Related articles
-
NewsAI used to create protein that kills E. coli
Scientists have used artificial intelligence (AI) to generate a ready-to-use biological protein that can kill antibiotic resistant bacteria like E. coli.
-
NewsInsights for future research and practical approaches in truncal acne
In a new study, researchers have systematically described the mechanisms of truncal acne, evaluated the methods and evaluated the mechanisms, targets, and pros/cons of several treatment products to guide clinical choices.
-
NewsFlightpath Biosciences licenses microbiome-sparing antibiotic developed at Illinois
Flightpath Biosciences, Inc., has licensed a class of antibiotics developed at the University of Illinois Urbana-Champaign. The original antibiotic agent, lolamicin, effectively treated bacterial infections in animal models of disease without wiping out beneficial gut microbes.
More from News
-
NewsClinical trials reveal promising alternatives to high-toxicity tuberculosis drug
Research shows two novel antibiotics could spare patients from severe side effects. The drugs sutezolid and delpazolid have demonstrated strong antimicrobial activity and a notably better safety profile compared to linezolid.
-
NewsProtecting the most vulnerable: ECDC recommendations to address ongoing local transmission of diphtheria
A new ECDC Rapid Risk Assessment highlights how ongoing circulation of diphtheria caused by Corynebacterium diphtheriae may affect some populations who are more vulnerable to infection and issues recommendations to protect those most at risk.
-
NewsCoral calcification benefits from human hormone injections
Researchers have identified how thyroxine, a human thyroid hormone, can positively influence the life-critical calcification in soft corals, and have developed a unique technique for injecting molecules into coral tissues.
No comments yet